What changed in Pfizer Inc's latest annual report
In the year ended 31 Dec 2025, Pfizer Inc's revenue fell 1.6% to USD 62.58bn, from USD 63.63bn; net income fell 3.2% to USD 7.77bn, from USD 8.03bn; cash and cash equivalents rose 9.5% to USD 1.14bn, from USD 1.04bn.
Year ended 31 Dec 2025. Source: 10-K filed 26 Feb 2026, read it on SEC EDGAR.
USD 63.63bn to USD 62.58bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 63.63bn | 62.58bn | Down 1.6% |
| Net income | 8.03bn | 7.77bn | Down 3.2% |
| Total assets | 213.40bn | 208.16bn | Down 2.5% |
| Total liabilities | 124.90bn | 121.39bn | Down 2.8% |
| Long-term debt | 57.41bn | 61.64bn | Up 7.4% |
| Cash and cash equivalents | 1.04bn | 1.14bn | Up 9.5% |
| Shareholders' equity | 88.20bn | 86.48bn | Down 2% |
Questions people ask
Did Pfizer Inc's revenue grow last year?
Revenue fell 1.6%, from USD 63.63bn to USD 62.58bn in the year ended 31 Dec 2025.
Is Pfizer Inc profitable?
Yes. Net income was USD 7.77bn in the year ended 31 Dec 2025. The year before: USD 8.03bn.
How much cash and debt does Pfizer Inc have?
At its latest year end (31 Dec 2025), Pfizer Inc reported cash and cash equivalents of USD 1.14bn and long-term debt of USD 61.64bn.
Where do these numbers come from?
From Pfizer Inc's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Pfizer Inc?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%
- Regeneron Pharmaceuticals, Inc.Cash and cash equivalents up 25.3%